Yes. Mitragynine is one of the 76 compounds in the LabX LC-MS/MS confirmation panel, reported as detected at or above 10 ng/mL. Mitragynine is not one of the 12 lines on the LabX 12-panel screen. It is identified by adding laboratory confirmation, which tests for all 76 compounds on the panel.
Mitragynine is the main active alkaloid in kratom, a plant from Southeast Asia sold in the United States as powders, capsules, drinks and extracts. It acts on opioid receptors, among other effects.
Also known as or found in: kratom.
Mitragynine and kratom are not FDA-approved medicines. Kratom's legal status varies by state and locality.
Mitragynine is measured by liquid chromatography with tandem mass spectrometry (LC-MS/MS), which separates the compounds in a sample and identifies each one by its mass. That is different from a rapid screen, which reacts to a family of drugs and can occasionally react to a related substance. The laboratory reports Mitragynine as detected when its concentration is at or above the cut-off of 10 ng/mL, within a reportable range of 10–1,000 ng/mL. It is one of 4 compounds in the fentanyl and novel opioids family on the 76-drug confirmation panel.
The laboratory's confirmation report does not print a standard detection window for Mitragynine. How long any compound stays measurable varies with the amount taken, how often it is used, metabolism and hydration, and a laboratory result cannot be used to work out when a substance was taken.
Mitragynine is not one of the 12 lines on the LabX 12-panel screen. It is identified by adding laboratory confirmation, which tests for all 76 compounds on the panel.
Kratom is not detected by standard drug screens. It is identified by laboratory confirmation testing that looks for mitragynine and the related compound 7-hydroxymitragynine.
Fentanyl and its metabolite, plus the main alkaloids in kratom. These are not reliably found by general opiate screens, which is why confirmation measures them directly.
Yes. Mitragynine is one of the 76 compounds in the LabX LC-MS/MS confirmation panel, reported as detected at or above 10 ng/mL. Mitragynine is not one of the 12 lines on the LabX 12-panel screen. It is identified by adding laboratory confirmation, which tests for all 76 compounds on the panel.
LabX reports Mitragynine as detected at or above 10 ng/mL, and the method's reportable range is 10–1,000 ng/mL. A result below the cut-off is reported as not detected; it does not prove none was present.
The laboratory report does not print a standard window for Mitragynine. Detection time varies with dose, frequency of use, metabolism and hydration.
Mitragynine is not one of the 12 lines on the LabX 12-panel screen. It is identified by adding laboratory confirmation, which tests for all 76 compounds on the panel.
Mitragynine and kratom are not FDA-approved medicines. Kratom's legal status varies by state and locality.
Terms on this page: metabolite · cut-off · detection window · presumptive result · confirmation test. More questions: LabX answers.
Test for Mitragynine and 75 other compounds
12-panel urine $89 or fingerstick blood $99, plus the 76-drug LC-MS/MS confirmation for +$89.
At-home drug tests and test kits are not currently available to addresses in New York, New Jersey, Rhode Island or California. Results are not a diagnosis — review them with a licensed physician.
Medical disclaimer. LabX Diagnostics and Vantage provide laboratory testing only. Test results and information on this site are for informational purposes and are not medical advice, diagnosis or treatment. Always consult a licensed physician or other qualified healthcare provider about your results and before making any health decision. If you think you may have a medical emergency, call 911. Read the full disclaimer.
Learn: 76-drug confirmation list · Drug library · Answers · How it works · Is LabX legit? · Glossary
